Keros Therapeutics reported a net loss of $7.3 million for the third quarter of 2025, compared to a net loss of $53.0 million for the same period in 2024. The decrease in net loss was primarily due to revenue recognized from Keros' license agreement with Takeda Pharmaceuticals, partially offset by ongoing research and development expenses and corporate investments. Research and development expenses decreased to $19.5 million from $49.2 million, mainly due to the transition of elritercept-related costs to Takeda. General and administrative expenses were $10.1 million, slightly up from $9.8 million, reflecting increased external expenses and a reduction in compensation costs following a headcount reduction. Cash and cash equivalents were $693.5 million as of September 30, 2025, up from $559.9 million at the end of 2024. Keros expects its cash reserves, after returning $375.0 million to shareholders, to fund operations into the first half of 2028. Key business developments include Takeda's plans to advance elritercept to a Phase 3 trial in myelodysplastic syndromes and Keros' progress toward a Phase 2 trial of KER-065 for Duchenne muscular dystrophy.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001664710-25-000086), on November 05, 2025, and is solely responsible for the information contained therein.
Comments